Phase 2
Completed N=23
Cathelicidin and Vitamin D: Impact on Populations At-Risk and With COPD
Pulmonary Disease, Chronic Obstructive
Source: ClinicalTrials.gov NCT02464059 ↗
Enrolled (actual)
23
Serious AEs
4.4%
Results posted
Jul 2020
Primary outcomePrimary: Change From Baseline in Lung Cathelicidin Level at 8 Weeks — -65.5 pg/mL — p=0.21
Summary
This proposal will evaluate a potential mechanism of increased risk of lung function impairment, cathelicidin levels, as well as determine if vitamin D replacement can alter this pathway. This study will improve the understanding of factors which can lead to chronic lung disease. If effective, this application would also provide the justification to study vitamin D as a therapy to improve lung health.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change From Baseline in Lung Cathelicidin Level at 8 Weeks |
-65.5 | 0.21 |
| SECONDARY Change From Baseline in Blood Cathelicidin at 8 Weeks |
-0.55 | 0.86 |
| SECONDARY Change From Baseline in Blood Vitamin D Binding Protein at 8 Weeks |
— | — |
Eligibility Criteria
Inclusion Criteria
- Men and women age 18-65 who are current or former smokers
- Serum calcium 2 liters/min via nasal cannula
- Any condition that, in the opinion of the site investigator, would compromise the subject's ability to participate in the study.
Data sourced from ClinicalTrials.gov (NCT02464059). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.